Nightstar Therapeutics plc
https://www.nightstartx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nightstar Therapeutics plc
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Biogen’s Q2 Highlights Need For Near-Term Successes
Second quarter performance was better than expected, but commercial weaknesses show the need for R&D wins and M&A deals as Tecfidera generics and aducanumab uncertainty weigh on the company.
30 Rising Leaders In The Life Sciences
Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut.
2020 Could Spell The End Of Mega-Mergers, For Now
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Nightstar Therapeutics Limited
- NightstaRx Ltd